Oxidative metabolism by P450 and function coupling to efflux systems: Modulation of mycotoxin toxicity

Food Additives and Contaminants

Volumn 22, Issue 4, 2005, Pages 361-368

  Aninat, C ^a   Andre F ^b,c   Delaforge, Marcel ^a,b  

^a Institut National de la Recherche Agronomique   (France)

^b CNRS   (France)

^c CEA SACLAY   (France)

Author keywords

Cyclosporin A; Cytochrome P450; Mycocotoxins; P glycoprotein; Roquefortine C

Indexed keywords

AFLATOXIN; CELL RECEPTOR; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 3A; ERGOT ALKALOID; FUMONISIN; GLYCOPROTEIN P; HEMOPROTEIN; MEMBRANE ENZYME; MYCOTOXIN; NEUROTOXIN; OCHRATOXIN; TRICHOTHECENE; XENOBIOTIC AGENT;

AEROBIC METABOLISM; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL PROTECTION; CYTOTOXICITY; DETOXIFICATION; ENZYME INHIBITION; HYDROPHOBICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; RECEPTOR BINDING; SCREENING; TOXICITY TESTING;

CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; INDOLES; METABOLIC DETOXICATION, DRUG; MYCOTOXINS; OXIDATION-REDUCTION; PIPERAZINES; XENOBIOTICS;

FUNGI; MAMMALIA; STAPHYLOCOCCUS PHAGE 3A;

EID: 19444367318     PISSN: 0265203X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02652030500073287     Document Type: Article

References (73)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. 1999. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual Review of Pharmacology and Toxicology 39:361-398.
2. André F, Pinet E. 1997. Tentoxin: structure-activity relationship. Application to the study of its action on chloroplast ATP-synthase. Compte-Rendus des Séances Societé de Biologie et de Filiales 191:401-432.
3. Aninat C, Hayashi Y, Andre F, Delaforge M. 2001. Molecular requirements for inhibition of cytochrome p450 activities by roquefortine. Chemical Research in Toxicology 14: 1259-1265.
4. Arnold DL, Scott PM, McGuire PF, Harwig J, Nera EA 1978. Acute toxicity studies on roquefortine and PR toxin metabolites of Penicillium roqueforti, in the mouse. Food Cosmetic Toxicology 16:369-371.
5. Bennett JW, Klich M. 2003. Mycotoxins. Clinical Microbiology Reviews 16:497-516.
6. Billaud EM, Ropers J, Fortineau N, Kreft-Jais C, Babanyu G. 1992. Critical analysis of drug interactions with cyclosporine. Evaluation of interactions with cyclosporine. Therapie 47: 335-342.
7. Buetler TM, Cottet-Maire F, Krauskopf A, Ruegg UT. 2000. Does cyclosporin A generate free radicals? Trends Pharmacological Sciences 21:288-290.
8. Burchell B, Coughtrie MW. 1997. Genetic and environmental factors associated with variation of human xenobiotic glucuronidation and sulfation. Environmental Health Perspective 105:739-747.
9. Chen HW, Chien CT, Yu SL, Lee YT, Chen WJ. 2002. Cyclosporine A regulate oxidative stress-induced apoptosis in cardiomyocytes: mechanisms via ROS generation, INOS and Hsp70. British Journal of Pharmacology 137:771-781.
10. Copeland KR, Yatscoff RW, Mckenna RM. 1990. Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance. Clinical Chemistry 36:225-229.
11. Cote LM, Dahlem AM, Yoshizawa T, Swanson SP, Buck WB. 1986. Excretion of deoxynivalenol and its metabolite in milk, urine, and feces of lactating dairy cows. Journal of Dairy Science 69:2416-2423.
12. Davies MJ, Fu S, Wang H, Dean RT. 1999. Stable markers of oxidant damage to proteins and their application in the study of human disease. Free radical in Biological Medicine 27:1151-1163.
13. Dean RT, Fu S, Stocker R, Davies MJ. 1997. Biochemistry and pathology of radical-mediated protein oxidation. Biochemical Journal 324:1-18.
14. Delaforge M, Riviere R, Sartori E, Doignon JL, Grognet JM. 1989. Metabolism of dihydroergotamine by a cytochrome P-450 similar to that involved in the metabolism of macrolide antibiotics. Xenobiotica 19:1285-1295.
15. Demeule M, Wenger RM, Beliveau R. 1997. Molecular interactions of cyclosporin A with P-glycoprotein. Photolabeling with cyclosporin derivatives. Journal of Biological Chemistry 272:6647-6652.
16. Dresser GK, Bailey DG. 2003. The effects of fruit juices on drug disposition: a new model for drug interactions. European Journal of Clinical Investigation 33(Suppl 2):10-16.
17. Ducharme MP, Warbasse LH, Edwards DJ. 1995. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clinical Pharmacology and Therapeutics 57:485-491.
18. Erhardt PW. 2003. A human drug metabolism database: potential roles in the quantitative predictions of drug metabolism and metabolism-related drug-drug interactions. Current Drug Metabolism 4:411-422.
19. Eze MO. 1992. Membrane fluidity, reactive oxygen species and cell-mediated immunity: implications in nutrition and disease. Medical Hypotheses 37:220-224.
20. Fu S, Fu MX, Baynes JW, Thorpe SR, Dean RT. 1998. Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins. Biochemical Journal 330:233-239.
21. Galtier P. 1999. Biotransformation and fate of mycotoxins. Journal of Toxicology-Toxin Reviews 18:295-312.
22. Garrigues A, Loiseau N, Delaforge M, Ferte J, Garrigos M, Andre F, Orlowski S. 2002. Characterization of Two Pharmacophores on the Multidrug Transporter P-Glycoprotein. Molecular Pharmacology 62:1288-1298.
23. Gelderblom WC, Snyman SD, Abel S, Lebepe-Mazur S, Smuts CM, Van Der Westhuizen L, Marasas WF, Victor TC, Knasmuller S, Huber W. 1996. Hepatotoxicity and carcinogenicity of the fumonisins in rats. A review regarding mechanistic implications for establishing risk in humans. Advances Experimental of Medicine and Biology 392:279-.296.
24. Goldstein A, Aronow L, Kalman SM, editors. 1974. Principles of drug action: The basis of pharmacology. New York: Wiley.
25. Graham RM. 1994. Cyclosporine: mechanisms of action and toxicity. Cleveland Clinic Journal of Medicine 61:308-313.
26. Guengerich FP. 1992. Metabolic activation of carcinogens. Pharmacology and Therapeutics 54:17-61.
27. Guengerich FP. 1995. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450: Structure, mechanism and biochemistry. New York: Academic Press. pp 537-574.
28. Guengerich FP 2003. Cytochrome P450 oxidations in the generation of reactive electrophiles: epoxidation and related reactions. Archives of Biochemistry and Biophysics 409:59-71.
29. Gursoy N, Bicici M. 2004. Review on current situation of toxigenic fungi and mycotoxins formation in Turkey. In: Logrieco A, Visconti A, editors. Overview of toxigenic fungi and mycotoxins; in Europe. Dordrecht: Kluwer. pp. 237-246.
30. Gutteridge JM. 1995. Lipid peroxidation and antoxidants as biomarkers of tissue damage. Clinical Chemistry 41:1819-1828.
31. Haberland A, Henke W, Grune T, Siems W, Jung K, Schimke I. 1997. Differential response of oxygen radical metabolism in rat heart, liver and kidney to cyclosporine A treatment. Inflammation Research 46:452-454.
32. Haggblom P. 1990. Isolation of Roquefortine C from Feed Grain. Applied Environmental and Microbiology 56:2924-2926.
33. Higuchi Y. 2003. Chromosomal DNA tragmentation in apoptosis and necrosis induced by oxidative stress. Biochemical Pharmacology 66:1527-1535.
34. Hollan S. 1996. Membrane fluidity of blood cells. Haematologia (Budap) 27:109-127.
35. Hosea NA, Miller GP, Guengerich FP. 2000. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39:5929-5939.
36. Hu MK, Badger A, Rich DH. 1995. Cyclosporin analogs modified in the 3,7,8-positions: substituent effects on peptidylprolyl isomerase inhibition and immunosppressive activity are non-additive. Journal of Medicinal Chemistry 38:4164-4170.
37. Hult K, Teiling A, Gatenbeck S. 1976. Degradation of ochratoxin A by a ruminant. Applied Environmental and Microbiology 32:443-444.
38. James LP, Mayeux PR, Hinson JA. 2003. Acetaminophen-induced hepatotoxicity. Drug Metabolism and Disposition 31:1499-1506.
39. Jegorov A, Matha V, Sedmera P, Havlicek V, Stuchlik J, Seidel P, Simek P. 1995. Cyclosporins from Tolypocladium terricola. Phytochemistry 38:403-497.
40. Kelly PA, Wang H, Napoli KL, Kahan BD, Strobel HW. 1999. Metabolism of cyclosporine by cytochromes P450 3A9 and 3A4. European Journal of Drug Metabolism and Pharmacokinetics 24:321-328.
41. Konig J, Nies AT, Cui Y, Leier I, Keppler D. 1999. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochimica Biophysica Acta 1461:377-394.
42. Kopp-Holtwiesche B, Rehm HJ. 1990. Antimicrobial action of roquefortine. Journal of Environmental Pathology Toxicology and Oncology 10:41-44.
43. Kullak-Ublick GA, Becker MB. 2003. Regulation of drug and bile salt transporters in liver and intestine. Drug Metabolism Review 35:305-317.
44. Leslie EM, Deeley RG, Cole SP. 2001. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167:3-23.
45. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. 1997. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clinical and Pharmacological Therapy 62:248-260.
46. Ludden TM. 1985. Pharmacokinetic interactions of the macrolide antibiotics. Clinical Pharmacokinetic 10:63-79.
47. Mannhold R, Rekker RF, Sonntag C, Ter Laak AM, Dross K Polymeropoulos EE. 1995. Comparative evaluation of the predictive power of calculated procedures for molecular lipophilicity. Journal of Pharmaceutical Sciences 84:1410-1419.
48. Mates JM. 2000. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 153:83-104.
49. Nadeem A, Chhabra SK, Masood A, Raj HG 2003. Increased oxidative stress and altered levels of antioxidants in asthma. Journal of Allergy and Clinical Immunology 111:72-78.
50. Ohmomo S, Sato T, Utagawa T, Abe M. 1975. Isolation of festuclavine and three new indole alkaloids, roquefortine A, B and C from the cultures of Penicillium roqueforti (production of alkaloids and related substances by fungi part XII). Journal of the Agricultural Chemical Society of Japan 49:615-623.
51. Orlowski S, Valente D, Garrigos M, Ezan E. 1998. Bromocriptine modulates P-glycoprotein function. Biochemical and Biophysical Research Communications 244:481-488.
52. Ortiz De Montellano PR. 1995. Cytochrome P450: Structure, mechanism and biochemistry. New York: Plenum.
53. Perret A, Pompon D. 1998. Electron shuttle between membrane-bound cytochrome P450 3A4 and b5 rules uncoupling mechanisms. Biochemistry 37:11412-11424.
54. Pfohl-Leszkowicz A, Chekir-Ghedira L, Bacha H. 1995. Genotoxicity of zearalenone, an estrogenic mycotoxin: DNA adduct formation in female mouse tissues. Carcinogenesis 16:2315-2320.
55. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G, Maurel P. 1990. Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metabolism and Disposition 18:595-606.
56. Ray G, Husain SA. 2002. Oxidants antioxidants and carcinogenesis. Indian Journal of Experimental Biology 40:1213-1232.
57. Repsgaard HH, Tsai L, Stadtman ER. 2000. Modifications of proteins by polyunsaturated fatty acid peroxidation products. Proceedings of the National Academy of Sciences, USA 97: 611-616.
58. Richard DJ, Schiavi B, Joullie MM. 2004. Synthetic studies of roquefortine C. synthesis of isoroquefortine C and a heterocycle. Proceedings of the National Academy of Sciences, USA 101:11971-11976.
59. Sagrista ME, Garcia AE, Africa de, Madariaga M, Mora M. 2002. Antioxidant and pro-oxidant effect of the thiolic compounds N-acetyl-L-cysteine and glutathione against free radical-induced lipid peroxidation. Free Radical Research 36:329-340.
60. Schellens JH, Malingre MM, Kruijtzer CM, Bardelmeijer HA, Van Tellingen O, Schinkel AH, Beijnen JH. 2000. Modulation of oral bioavailability of anticancer drugs from mouse to man. European Journal of Pharmaceutical Sciences 12:103-110.
61. Schiavi BM, Richard DJ, Joullie MM. 2002. Total synthesis of isoroquefortine C. Journal of Organic Chemistry 67:620-624.
62. Schinkel AH 1997. The physiological function of drug-transporting P-glycoproteins. Seminars in Cancer Biology 8: 161-170.
63. Schmitt L, Tampe R. 2002. Structure and mechanism of ABC transporters. Current Opinion in Structural Biology 12:754-760.
64. Sharma R, Yang Y, Sharma A, Awasthi S, Awasthi YC. 2004. Antioxidant role of glutathione S-transferases protection against oxidant toxicity and regulation of stress-mediated apoptosis. Antioxidant Redox Signal 6:289-300.
65. Uchida K, Szweda LI, Chae HZ, Stadtman ER. 1993. Immunochemical detection of 4-hydroxynonenal protein adducts in oxidized hepatocytes. Proceedings of the National Academy of Sciences, USA 90:8742-8746.
66. Vatsis KP, Coon MJ. 2002. Ipso-substituition by cytochrome P450 with conversion of P-hydroxybenzene derivatives to hydroquinone: evidence for hydroperoxo-iron as the active oxygen species. Archives of Biochemistry and Biophysics 397:11-129.
67. Vickers AE, Fischer V, Connors S, Fisher RL, Baldeck JP, Maurer G, Brendel K. 1992. Cyclosporin A metabolism in human liver, kidney, and intestine slices. Comparison to rat and dog slices and human cell lines. Drug Metabolism and Disposition 20:802-809.
68. Von Rosensteil NA, Adam D. 1995. Macrolide antibacterials. Drug interactions of clinical significance. Drug Safety 13:105-122.
69. Wood LG, Gibson PG, Garg ML. 2003. Biomarkers of lipid peroxidation, airway inflammation and asthma. European Respiratory Journal 21:177-186.
70. Woodland C, Koren G, Wainer IW, Batist G, Ito S. 2003. Verapamil metabolites: potential P-glycoprotein-mediated multidrug resistance reversal agents. Canadian Journal of Physiology and Pharmacology 81:800-805.
71. Woolf TF, editor. 1999. Handbook of Drug Metabolism. New York: Marcel Dekker.
72. Wu D, Cederbaum AI. 2003. Alcohol oxidative stress and free radicat damage Alcohol Research Health 27:277-284.
73. Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Ashahi S, Shimada N, Guengerich FP, Shimada T, Nakajima M, Yokoi T. 2002. Roles of NADPH-P450 reductase and apo- and holocytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expression Purification 24:329-337.